VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Agarwal on Candidates for Docetaxel Versus Abiraterone and Prednisone

Neeraj Agarwal, MD
Published: Monday, Jul 31, 2017



Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses how to determine which patient with prostate cancer is a candidate for docetaxel versus abiraterone acetate (Zytiga) and prednisone.

If a patient has a high-volume of disease, docetaxel is most likely the best option, according to Agarwal. However, if a patient has a low-volume disease, Agarwal would be more inclined to offer abiraterone and prednisone.

Research still needs to be conducted to develop biomarkers to better determine the treatment for these patients, states Agarwal.



Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses how to determine which patient with prostate cancer is a candidate for docetaxel versus abiraterone acetate (Zytiga) and prednisone.

If a patient has a high-volume of disease, docetaxel is most likely the best option, according to Agarwal. However, if a patient has a low-volume disease, Agarwal would be more inclined to offer abiraterone and prednisone.

Research still needs to be conducted to develop biomarkers to better determine the treatment for these patients, states Agarwal.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x